Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Sangamo Therapeutics's share price for the quarter that ended in Mar. 2026 was $0.2352. Sangamo Therapeutics's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 414.27 Mil. Therefore, Sangamo Therapeutics's market cap for the quarter that ended in Mar. 2026 was $97.44 Mil.
Sangamo Therapeutics's quarterly market cap
declined
from Sep. 2025 ($208.73 Mil) to Dec. 2025 ($145.15 Mil) and
declined
from Dec. 2025 ($145.15 Mil) to Mar. 2026 ($97.44 Mil).
Sangamo Therapeutics's annual market cap
increased
from Dec. 2023 ($98.56 Mil) to Dec. 2024 ($220.29 Mil) but then
declined
from Dec. 2024 ($220.29 Mil) to Dec. 2025 ($145.15 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Sangamo Therapeutics's Enterprise Value for Today is $22.40 Mil.
Sangamo Therapeutics (LTS:0R1D) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Sangamo Therapeutics Market Cap Related Terms
Sangamo Therapeutics Market Cap Historical Data
* Premium members only.
The historical data trend for Sangamo Therapeutics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0R1D vs SER, ABVC, PLRZ: Market Cap Comparison
For the Biotechnology subindustry, Sangamo Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sangamo Therapeutics Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sangamo Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where Sangamo Therapeutics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Sangamo Therapeutics's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sangamo Therapeutics (LTS:0R1D) has a Market Cap of $30.66 Mil as of Aug. 07, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Sangamo Therapeutics and its competitors. According to the industry distribution chart, Sangamo Therapeutics ranks #1000 out of 1423 companies in the Biotechnology industry, placing it in the top 70.3%.
Is Sangamo Therapeutics' Market Cap too high?
Sangamo Therapeutics' current Market Cap is $30.66 Mil. The Biotechnology industry median Market Cap is 116.70. Sangamo Therapeutics' value of $30.66 Mil is 73.7% below this industry median. Based on the distribution chart, Sangamo Therapeutics ranks #1000 out of 1423 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Sangamo Therapeutics has a GF Score™ of 35/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sangamo Therapeutics' Market Cap compare to SER and ABVC?
According to the Biotechnology industry distribution chart, Sangamo Therapeutics ranks #1000 out of 1423 companies for Market Cap. This places Sangamo Therapeutics in the lower half of its industry. The industry median Market Cap is 116.70. Sangamo Therapeutics' value of $30.66 Mil is 73.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 116.70, based on 1,423 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sangamo Therapeutics's current Market Cap of $30.66 Mil is 73.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Sangamo Therapeutics and its competitors. For the Biotechnology industry, the median Market Cap is 116.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sangamo Therapeutics's current Market Cap is $30.66 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sangamo Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Sangamo Therapeutics (LTS:0R1D) is currently considered Possible Value Trap. The stock's GF Value™ is $0.19, compared to a current price of $0.11 — trading 42.2% below its estimated fair value. The current Market Cap is $30.66 Mil and 73.7% below the Biotechnology industry median of 116.70. Sangamo Therapeutics' overall GF Score™ is 35/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Sangamo Therapeutics (LTS:0R1D), the current Market Cap is $30.66 Mil as of Aug. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sangamo Therapeutics (LTS:0R1D) Overvalued in 2026?
Based on GuruFocus' analysis, Sangamo Therapeutics stock appears to be undervalued.
The current stock price of $0.11 is trading 42.2% below its estimated GF Value™ of $0.19.
GuruFocus considers Sangamo Therapeutics to be Possible Value Trap.
Key valuation signals for LTS:0R1D:
Market Cap: $30.66 Mil
GF Value™: $0.19 vs. price of $0.11 (42.2% below fair value)
Industry Position: 73.7% below the Biotechnology median (#1000 of 1423)
No single metric tells the full story. See the LTS:0R1D stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its neurology development is focused on two areas: development of epigenetic regulation therapies to treat serious neurological diseases and development of novel engineered adeno-associated virus, or AAV, capsids to deliver its therapies to the intended neurological targets. The group's pipeline products are Small Fiber Neuropathy, Prion Disease, Tauopathies, ALS/FTD, Huntington's Disease, Fabry Disease, and Hemophilia A.
35GF Score
Get the complete analysis for LTS:0R1D
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0R1D has been successfully added to your 
